Making a case “against” focal therapy for intermediate-risk prostate cancer

[1]  M. Sydes,et al.  Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. , 2020, Contemporary clinical trials.

[2]  J. Cadeddu.  Re: Comparison of Outcomes of Salvage Robot-Assisted Laparoscopic Prostatectomy for Post-Primary Radiation vs Focal Therapy. , 2020, The Journal of urology.

[3]  G. Marra,et al.  Re: Lorenzo Marconi, Thomas Stonier, Rafael Tourinho-Barbosa, et al. Robot-assisted Radical Prostatectomy After Focal Therapy: Oncological, Functional Outcomes and Predictors of Recurrence. Eur Urol 2019;76:27-30: Salvage Robotic Radical Prostatectomy for Recurrent Prostate Cancer After Focal Therap , 2020, European urology.

[4]  A. Rosenkrantz,et al.  Factors Influencing Variability in the Performance of Multiparametric Magnetic Resonance Imaging in Detecting Clinically Significant Prostate Cancer: A Systematic Literature Review. , 2020, European urology oncology.

[5]  C. Ogden,et al.  Evaluation of functional outcomes after a second focal high‐intensity focused ultrasonography (HIFU) procedure in men with primary localized, non‐metastatic prostate cancer: results from the HIFU Evaluation and Assessment of Treatment (HEAT) registry , 2020, BJU international.

[6]  H. Ahmed,et al.  PSA Criteria to Diagnose Failure of Cancer Control following Focal Therapy for Non-metastatic Prostate Cancer Using High Intensity Focused Ultrasound. , 2020, The Journal of urology.

[7]  T. Peters,et al.  Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. , 2019, European urology.

[8]  C. Stief,et al.  Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials). , 2019, European urology focus.

[9]  H. G. van der Poel,et al.  Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches. , 2019, The Journal of urology.

[10]  M. Baghdadi,et al.  Multimodal treatment in Focal Therapy for localized prostate cancer using concomitant short-term androgen deprivation therapy: the ENHANCE prospective pilot study. , 2019, Minerva urologica e nefrologica = The Italian journal of urology and nephrology.

[11]  M. Emberton,et al.  Salvage Local Treatments After Focal Therapy for Prostate Cancer. , 2019, European urology oncology.

[12]  F. Montorsi,et al.  Medium‐term oncological outcomes in a large cohort of men treated with either focal or hemi‐ablation using high‐intensity focused ultrasonography for primary localized prostate cancer , 2019, BJU international.

[13]  S. Raman,et al.  Do contemporary imaging and biopsy techniques reliably identify unilateral prostate cancer? Implications for hemiablation patient selection , 2019, Cancer.

[14]  M. Moschini,et al.  Focal Therapy for Localized Prostate Cancer with Either HIFU or Cryoablation: A Single Institution Experience. , 2019, The Journal of urology.

[15]  I. Gill,et al.  Hemigland Cryoablation of Localized Low, Intermediate and High Risk Prostate Cancer: Oncologic and Functional Outcomes at 5 Years , 2019, Journal of Urology.

[16]  H. Ahmed,et al.  Early-Medium-Term Outcomes of Primary Focal Cryotherapy to Treat Nonmetastatic Clinically Significant Prostate Cancer from a Prospective Multicentre Registry. , 2019, European urology.

[17]  A. Freeman,et al.  Pathological Findings and Magnetic Resonance Imaging Concordance at Salvage Radical Prostatectomy for Local Recurrence following Partial Ablation Using High Intensity Focused Ultrasound , 2019, The Journal of urology.

[18]  D. Lu,et al.  Detection of Individual Prostate Cancer Foci via Multiparametric Magnetic Resonance Imaging. , 2019, European urology.

[19]  M. Haider,et al.  Multiparametric Magnetic Resonance Imaging for Prostate Cancer Detection: What We See and What We Miss. , 2019, European urology.

[20]  Bradford J. Wood,et al.  Analyzing the current practice patterns and views among urologists regarding focal therapy for prostate cancer. , 2019, Urologic oncology.

[21]  David Lu,et al.  Three Tesla Multiparametric Magnetic Resonance Imaging: Comparison of Performance with and without Endorectal Coil for Prostate Cancer Detection, PI-RADS™ version 2 Category and Staging with Whole Mount Histopathology Correlation , 2019, The Journal of urology.

[22]  M. Papotti,et al.  Prostate cancer detection with biparametric magnetic resonance imaging (bpMRI) by readers with different experience: performance and comparison with multiparametric (mpMRI) , 2019, Abdominal Radiology.

[23]  J. Walz,et al.  Complications, oncological and functional outcomes of salvage treatment options following focal therapy for localized prostate cancer: a systematic review and a comprehensive narrative review , 2019, World Journal of Urology.

[24]  J. Futterer,et al.  Controversies in MR targeted biopsy: alone or combined, cognitive versus software-based fusion, transrectal versus transperineal approach? , 2019, World Journal of Urology.

[25]  J. W. Yu,et al.  Combination of multiparametric magnetic resonance imaging and transrectal ultrasound-guided prostate biopsies is not enough for identifying patients eligible for hemiablative focal therapy for prostate cancer , 2019, World Journal of Urology.

[26]  S. Albisinni,et al.  Cartography-based quality control of prostate cancer care: a necessary ground to targeted focal therapy , 2019, Current opinion in urology.

[27]  R. V. D. van den Bergh,et al.  Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. , 2018, Urologic oncology.

[28]  P. Validire,et al.  The clinical role of the TME in solid cancer , 2018, British Journal of Cancer.

[29]  J. J. de la Rosette,et al.  Prostate cancer multifocality, the index lesion, and the microenvironment , 2018, Current opinion in urology.

[30]  P. Gontero*,et al.  Retreatment after focal therapy for failure: a bridge too far? , 2018, Current opinion in urology.

[31]  F. Hamdy,et al.  Partial ablation versus radical prostatectomy in intermediate-risk prostate cancer: the PART feasibility RCT. , 2018, Health technology assessment.

[32]  H. Hricak,et al.  Temporal changes in MRI appearance of the prostate after focal ablation , 2018, Abdominal Radiology.

[33]  H. G. van der Poel,et al.  Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. , 2018, European urology.

[34]  J. Kench,et al.  Surveillance after prostate focal therapy , 2018, World Journal of Urology.

[35]  A. Rosenkrantz,et al.  The Institutional Learning Curve of Magnetic Resonance Imaging‐Ultrasound Fusion Targeted Prostate Biopsy: Temporal Improvements in Cancer Detection in 4 Years , 2018, The Journal of urology.

[36]  F. Montorsi,et al.  Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. , 2018, European urology oncology.

[37]  A. Cestari,et al.  Which technology to select for primary focal treatment of prostate cancer?—European Section of Urotechnology (ESUT) position statement , 2018, Prostate Cancer and Prostatic Diseases.

[38]  Yi Mi Wu,et al.  The long tail of oncogenic drivers in prostate cancer , 2018, Nature Genetics.

[39]  P. Stattin,et al.  Factors Influencing Men's Choice of and Adherence to Active Surveillance for Low-risk Prostate Cancer: A Mixed-method Systematic Review. , 2018, European urology.

[40]  H. G. van der Poel,et al.  What Is the Negative Predictive Value of Multiparametric Magnetic Resonance Imaging in Excluding Prostate Cancer at Biopsy? A Systematic Review and Meta-analysis from the European Association of Urology Prostate Cancer Guidelines Panel. , 2017, European urology.

[41]  E. Messing,et al.  Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology , 2017, The Journal of urology.

[42]  R. Popert,et al.  Pathological Concordance between Prostate Biopsies and Radical Prostatectomy Using Transperineal Sector Mapping Biopsies: Validation and Comparison with Transrectal Biopsies , 2017, Urologia Internationalis.

[43]  V. Ficarra,et al.  Multiparametric Magnetic Resonance Imaging Targeted Biopsy for Early Detection of Prostate Cancer: All That Glitters Is Not Gold! , 2017, European urology.

[44]  Jurgen J Fütterer,et al.  Why and Where do We Miss Significant Prostate Cancer with Multi-parametric Magnetic Resonance Imaging followed by Magnetic Resonance-guided and Transrectal Ultrasound-guided Biopsy in Biopsy-naïve Men? , 2017, European urology.

[45]  M. Cooperberg,et al.  THE INFLUENCE OF PSYCHOSOCIAL CONSTRUCTS ON THE ADHERENCE TO ACTIVE SURVEILLANCE FOR LOCALIZED PROSTATE CANCER IN A PROSPECTIVE, POPULATION‐BASED COHORT: PD28‐04 , 2017 .

[46]  F. Hamdy,et al.  THE PART TRIAL ‐ A PHASE III STUDY COMPARING PARTIAL PROSTATE ABLATION VERSUS RADICAL PROSTATECTOMY (PART) IN INTERMEDIATE RISK PROSTATE CANCER – EARLY DATA FROM THE FEASIBILITY STUDY: PD56‐08 , 2017 .

[47]  M. Parmar,et al.  Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): a paired validating confirmatory study , 2017, The Lancet.

[48]  Antonio Alcaraz,et al.  Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial. , 2017, The Lancet. Oncology.

[49]  Alain Bergeron,et al.  Genomic hallmarks of localized, non-indolent prostate cancer , 2017, Nature.

[50]  M. Roethke,et al.  Multiparametric Magnetic Resonance Imaging (MRI) and MRI-Transrectal Ultrasound Fusion Biopsy for Index Tumor Detection: Correlation with Radical Prostatectomy Specimen. , 2016, European urology.

[51]  P. Gontero*,et al.  Changing the prostate cancer management pathway: why Focal Therapy is a step forward. , 2016, Archivos espanoles de urologia.

[52]  E. Barret,et al.  Focal Therapy for Prostate Cancer: An "À la Carte" Approach. , 2016, European urology.

[53]  D. Moses,et al.  Combination of multiparametric MRI and transperineal template‐guided mapping biopsy of the prostate to identify candidates for hemi‐ablative focal therapy , 2016, BJU international.

[54]  Steven J. M. Jones,et al.  The Molecular Taxonomy of Primary Prostate Cancer , 2015, Cell.

[55]  M. Dall’Era.  Patient and disease factors affecting the choice and adherence to active surveillance , 2015, Current opinion in urology.

[56]  J. Bernhard,et al.  Magnetic resonance imaging-transectal ultrasound image-fusion biopsies accurately characterize the index tumor: correlation with step-sectioned radical prostatectomy specimens in 135 patients. , 2015, European urology.

[57]  J. Trachtenberg,et al.  The Role of Focal Therapy in the Management of Localised Prostate Cancer: A Systematic Review , 2014, European urology.

[58]  T. Wilt,et al.  Can we deliver randomized trials of focal therapy in prostate cancer? , 2014, Nature Reviews Clinical Oncology.

[59]  M. Emberton,et al.  Management of low risk prostate cancer—active surveillance and focal therapy , 2014, Nature Reviews Clinical Oncology.

[60]  E. Barret,et al.  How to diagnose and treat focal therapy failure and recurrence? , 2014, Current opinion in urology.

[61]  Johan Lindberg,et al.  The mitochondrial and autosomal mutation landscapes of prostate cancer. , 2013, European urology.

[62]  T. H. van der Kwast,et al.  Salvage radical prostatectomy following primary high intensity focused ultrasound for treatment of prostate cancer. , 2011, The Journal of urology.

[63]  Hashim Uddin Ahmed,et al.  The index lesion and the origin of prostate cancer. , 2009, The New England journal of medicine.

[64]  Jun Luo,et al.  Copy Number Analysis Indicates Monoclonal Origin of Lethal Metastatic Prostate Cancer , 2009, Nature Medicine.

[65]  Xavier Leroy,et al.  Peripheral zone prostate cancers: Location and intraprostatic patterns of spread at histopathology , 2009, The Prostate.

[66]  R. Shah,et al.  Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.

[67]  Thomas J. Polascik,et al.  Focal therapy for prostate cancer , 2008, Current opinion in urology.

[68]  J. Moul,et al.  Prostate cancer laterality as a rationale of focal ablative therapy for the treatment of clinically localized prostate cancer , 2007, Cancer.

[69]  C. Ogden,et al.  Evaluation of functional outcomes following a second focal-HIFU in men with primary localised, non-metastatic prostate cancer; Results from the High Intensity Focused Ultrasound Evaluation and Assessment of Treatment (HEAT) Registry , 2020 .

[70]  H. Ahmed,et al.  ROBOTIC ASSISTED RADICAL PROSTATECTOMY AFTER FOCAL THERAPY:ONCOLOGICAL, FUNCTIONAL OUTCOMES AND PREDICTORS OF RECURRENCE , 2019 .

[71]  Baris Turkbey,et al.  What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. , 2018, Radiology.

[72]  E. Messing,et al.  A Comprehensive Analysis of Cribriform Morphology on Magnetic Resonance Imaging/Ultrasound Fusion Biopsy Correlated with Radical Prostatectomy Specimens , 2018, The Journal of urology.

[73]  Mark Emberton,et al.  New and Established Technology in Focal Ablation of the Prostate: A Systematic Review. , 2017, European urology.